Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of 177Lu‐PSMA‐617 in prostate cancer patients
Open Access
- 9 February 2023
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 12 (8) , 1060-1071
Abstract
Studies to evaluate and optimize [177Lu]Lu‐PSMA treatment focus primarily on individual patient data. A population pharmacokinetic (PK) dosimetry model was developed to explore the potential of using imaging data as input for population PK models and to characterize variability in organ and tumor uptake of [177Lu]Lu‐PSMA‐617 in patients with low volume metastatic prostate cancer. Simulations were performed to identify the effect of dose adjustments on absorbed doses in salivary glands and tumors. A six‐compartment population PK model was developed, consisting of blood, salivary gland, kidneys, liver, tumor, and a lumped compartment representing other tissue (compartment 1–6, respectively), based on data from 10 patients who received [177Lu]Lu‐PSMA‐617 (2 cycles, ~ 3 and ~ 6 GBq). Data consisted of radioactivity levels (decay corrected) in blood and tissues (9 blood samples and 5 single photon emission computed tomography/computed tomography scans). Observations in all compartments were adequately captured by individual model predictions. Uptake into salivary glands was saturable with an estimated maximum binding capacity (Bmax) of 40.4 MBq (relative standard error 12.3%) with interindividual variability (IIV) of 59.3% (percent coefficient of variation [CV%]). IIV on other PK parameters was relatively minor. Tumor volume was included as a structural effect on the tumor uptake rate constant (k15), where a two‐fold increase in tumor volume resulted in a 1.63‐fold increase in k15. In addition, interoccasion variability on k15 improved the model fit (43.5% [CV%]). Simulations showed a reduced absorbed dose per unit administered activity for salivary glands after increasing radioactivity dosing from 3 to 6 GBq (0.685 Gy/GBq vs. 0.421 Gy/GBq, respectively). All in all, population PK modeling could help to improve future radioligand therapy research.Keywords
This publication has 32 references indexed in Scilit:
- Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate CancerJournal of Nuclear Medicine, 2015
- Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practiceProstate International, 2014
- The prostate-specific membrane antigen: Lessons and current clinical implications from 20 years of researchUrologic Oncology: Seminars and Original Investigations, 2014
- Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling MethodsCPT: Pharmacometrics & Systems Pharmacology, 2013
- Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kineticsAsian Journal of Andrology, 2012
- Regulation of hepatic blood flow: The hepatic arterial buffer response revisitedWorld Journal of Gastroenterology, 2010
- MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of NomenclatureJournal of Nuclear Medicine, 2009
- Population Pharmacokinetics III: Design, Analysis, and Application of Population Pharmacokinetic StudiesAnnals of Pharmacotherapy, 2004
- Comparative analysis of prostate‐specific membrane antigen (PSMA) versus a prostate‐specific membrane antigen‐like geneThe Prostate, 2003
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976